CLAIMS

SUB:

10

15

- 1. An enzyme having AHCY-type activity which includes amino acids 177 to 314 of the amino acid sequence of Figure 1, or a functional portion or functional equivalent of said enzyme.
- 2. An enzyme according to claim 1 which comprises amino acids 183 to 614 of the amino acid sequence of Figure 1.
- 3. An enzyme according to claim 1 which comprises amino acids 1 to 614 of the amino acid sequence of Figure 1.
- 4. An isolated DNA sequence comprising a nucleotide sequence selected from the group consisting of:
 - (a) a sequence which encodes an enzyme according to claim 1 or a functional portion or equivalent thereof:
 - (b) a sequence which is a complement of a sequence (a);
 - (c) a sequence which is a reverse complement of a sequence (a); and
 - (d) a sequence which is a reverse sequence of a sequence (a).
- 5. A DNA sequence according to claim 4 in which sequence (a) comprises nucleotides 529 to 945 of the Figure 1 sequence.
- 6. A DNA sequence according to claim 4 in which sequence (a) comprises nucleotides 549 to 1844 of the Figure 1 sequence.

SUB²⁵

30

576MGW1

- 7. A DNA sequence according to claim 4 in which sequence (a) comprises nucleotides 1 to 1844 of the Figure 1 sequence.
- 8. A DNA construct comprising a DNA sequence according to any one of claims 4
- 9. A DNA construct comprising, in the 5'-3' direction.:
 - (a) a gene promoter sequence;

- an open reading frame coding for at least a functional portion of an (b) enzyme according to claim 1; and
- (c) a gene termination sequence.
- 5 A DNA construct according to claim 9 wherein the open reading frame is in a 10. sense orientation.
 - A DNA construct according to claim 9 wherein the open reading frame is in an 11. anti-sense orientation.

10

15

- A DNA construct comprising, in the 5'-3' direction.: 12.
 - (a) a gene promoter sequence;
 - a non-coding region of a gene coding for an enzyme according to claim (b) 1; and
 - (c) a gene termination sequence.

The floor first and first of the first

A method for modulating the activity of an enzyme according to claim 1 in a 13. patient, comprising administering to said patient a DNA construct according to any one of claims 8 to λ 2.

- A method of amplifying the activity of an enzyme according to claim 1 in a 14. patient comprising administering to said patient a DNA construct according to claim 10.
- A method of supressing the activity_of an enzyme according to claim 1 in a 25 15. patient comprising administering to said patient a DNA construct according to claim 11 or claim 12.
- A method of determining the modulatory potential of a compound on an enzyme 16. 30 according to claim 1 which comprises the step of determining the ability of said compound to modulate the activity of said enzyme.
 - An antibody which binds an enzyme according to claim 1. 17.



SUS CH

18. An optionally labelled nucleic acid probe capable of hybridising, under high stringency, to a nucleotide sequence of Figure 1.